Ad hoc: Medigene and SynCore enter into Co-Development and Commercialization Agreement for EndoTAG®-1


06.07.12 17:00
Meldung
 
Ad hoc: <strong>Medigene</strong> and SynCore enter into Co-Development and Commercialization Agreement for EndoTAG®-1

MediGene AG /Ad hoc: Medigene and SynCore enter into Co-Development and Commercialization Agreement for EndoTAG®-1 . Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

  • SynCore receives exclusive rights to co-develop and commercialize EndoTAG®-1 in Asia, Australia and New Zealand  

  • Medigene retains all US, European and remaining RoW rights 

  • Medigene will receive an upfront, milestone payments and royalties  

  • Medigene plans global pivotal phase III trial in triple-negative breast cancer (TNBC) 

  • SynCore will assume costs for the Asian part of the global pivotal phase III trial  

Martinsried/Munich, July 6, 2012. Medigene AG (Frankfurt: MDG, Prime Standard) announced that it has granted exclusive rights for co-development and commercialization of EndoTAG®-1 in Asia, Australia and New Zealand to SynCore Biotechnology Co., Ltd. ("SynCore"), a subsidiary of the Sinphar Pharmaceutical Group (Taiwan Stock Exchange, Symbol: 1734).

Medigene plans a pivotal global phase III trial of EndoTAG®-1 in triple-negative breast cancer (TNBC) with the aim of achieving worldwide market approval. Under the terms of the agreement, SynCore will fund the Asian part of the clinical trial, representing about 50% of the total number of patients to be included. Subject to clinical trial approval, approximately 400 patients are expected to be enrolled in the global pivotal phase III trial in TNBC. Furthermore, Medigene receives an upfront payment from SynCore and is eligible to payments upon certain development and approval milestones as well as royalties. Medigene retains all US, European and remaining rest-of-the-world (RoW) rights to EndoTAG®-1 with the ability to grant further licenses. Medigene anticipates submission for market approval for EndoTAG®-1 in 2018.

The agreement does not impact Medigene's financial guidance for 2012 and the management confirms that the company's funding is expected to be secured beyond 2013.

For more information please see today's press release at http://www.medigene.com/press

- End -

Contact

Julia Hofmann & Kerstin Langlotz

Tel.: +49 - 89 - 20 00 33 - 33 01

Fax: +49 - 89 - 20 00 33 - 29 20

Email: investor@medigene.com

ad hoc release as pdf









The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the

information contained therein.



Source: MediGene AG via Thomson Reuters ONE

HUG#1624967

--- End of Message ---



MediGene AG

Lochhamer Strasse 11 Martinsried / München Germany



WKN: 502090;ISIN: DE0005020903;

Listed: Freiverkehr in Börse Stuttgart,

Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,

Freiverkehr in Börse Düsseldorf,

Freiverkehr in Bayerische Börse München,

Freiverkehr in Niedersächsische Börse zu Hannover,

Prime Standard in Frankfurter Wertpapierbörse,

Regulierter Markt in Frankfurter Wertpapierbörse;





 

Kurs- und weitere Informationen zum Thema:

Medigene

Aktuelle Diskussionen zum Thema:

Medigene, Meinungen, daily talk, ... (02.09.14)
Medigene Chartanalyse (14.01.14)
MEDIGENE neu ! A1X3W0 (15.10.13)

Aktuelle Nachrichten zum Unternehmen:

Medigene-Aktie: Kursziel nach Q2-. (12.08.14)
Medigene H1-Halbjahreszahlen: Ges. (07.08.14)
GNW-News: Medigene verbessert . (07.08.14)
Medigene: Tochter Trianta gibt Ve. (22.07.14)
Medigene: Veregen kommt in Kana. (17.07.14)

Alle Nachrichten zum Unternehmen

Aktuelle Analysen zu den Unternehmen:

Medigene
Weitere Meldungen
 
11.07 Ad hoc: ALNO AG setzt u.
10.07 Ad hoc: centrotherm photovo.
10.07 Ad hoc: Neuer institutionelle.
10.07 Ad hoc: Value Management .
10.07 Ad hoc: TOMORROW FOCU.
10.07 Ad hoc: AEVIS Holding SA.
10.07 Ad hoc: Graphit Kropfmühl .
10.07 Ad hoc: Catalis SE: Catalis .
10.07 Ad hoc: Solar-Fabrik Aktien.
10.07 Ad hoc: 118000 AG noch .
10.07 Ad hoc: CinemaxX AG: Bev.
10.07 DGAP-WpÜG: Übernahmeang.
10.07 Ad hoc: Linde AG: Ad-hoc-.
10.07 Ad hoc: Linde AG: Ad-hoc-.
10.07 Ad hoc: MOLOGEN AG Ka.
10.07 Ad hoc: AEVIS Holding SA.
10.07 Ad hoc: CureBeta, eine Koo.
09.07 Ad hoc: Linde AG: Ad-hoc-.
09.07 Ad hoc: Linde AG: Ad-hoc-.
09.07 Ad hoc: Vorstand der Comp.
09.07 Ad hoc: Oceanica AG: Amt.
09.07 Ad hoc: Solarparc AG: Hand.
09.07 Ad hoc: Kremlin AG: Portfo.
09.07 Ad hoc: Wolford AG: Ad h.
09.07 Ad hoc: nebag ag / Kapital.
06.07 Ad hoc: WILEX AG entsch.
06.07 Ad hoc: Medigene and SynC.
06.07 Ad hoc: Medigene und SynC.
06.07 Ad hoc: WMF Württemberg.
06.07 DGAP-WpÜG: Übernahmeang.


Umfrage
 
Welche Social Networks nutzen Sie meistens?
Facebook
keine
Twitter
Xing
Linked in
Youtube
myspace
Google+
Wikipedia
andere


Stimmen: 6782 , Ergebnis


Kurssuche
Status: nicht eingeloggt

Registrieren | Passwort vergessen?
 
 
Im Bereich Nachrichten:
Nordex SE: der nächste Versuch!
Experte: Stefan Hofmann, STOCK-WORLD
Kolumnen
Vermögensverwalter kaufen ...
Jürgen Lampe, firstfive (20:33)
Experte: Jürgen Lampe, firstfive
DAX vor einem neuen ...
Thomas Heydrich, Systemstrading.de (20:29)
Experte: Thomas Heydrich, Systemstrading.de
Vodis Pharmaceuticals: Top-...
Claudius Strehlau, shareribs.com (18:15)
Experte: Claudius Strehlau, shareribs.com
Draghi im Nacken – Dax ...
IG Markets, (17:27)
Experte: IG Markets,
DAX volatiler vor EZB-...
Jens Klatt, Chefanalyst von DailyFX (17:12)
Experte: Jens Klatt, Chefanalyst von DailyFX
ETFs: Raus aus Europa, ...
Redaktion boerse-frankf., Deutsche Börse AG (16:31)
Experte: Redaktion boerse-frankfurt.de, Deutsche Börse AG
K+S - Ducks of the DAX
Kemal Bagci, RBS (16:11)
Experte: Kemal Bagci, RBS
Trading-Update für 15:45 ...
Berndt Ebner, Der-Trading-Coach.com (15:54)
Experte: Berndt Ebner, Der-Trading-Coach.com
Vernetzung mit Börse ...
Feingold-Research, (15:28)
Experte: Feingold-Research,
Überraschung: Tipp24 ...
Cornelia Frey, Börse Stuttgart AG (14:48)
Experte: Cornelia Frey, Börse Stuttgart AG
S&P-500-Index - Stopp ...
Jürgen Sterzbach, www.boerse-daily.de (14:24)
Experte: Jürgen Sterzbach, www.boerse-daily.de
Nordex SE: der nächste ...
Stefan Hofmann, STOCK-WORLD (14:16)
Experte: Stefan Hofmann, STOCK-WORLD
Niquet's World
Neues vom Portal
 
Wertpapierdepot der 1822direkt: Attraktives Angebot für kostenbewusste ...
Letzte Börsen-Meldung
 
Letzte Börsen-Analyse
 
Top-Klicks News
 
Top-Klicks Analysen